• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Niklason Laura E

    10/15/21 3:39:02 PM ET
    $AHAC
    Business Services
    Finance
    Get the next $AHAC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Niklason Laura E

    (Last) (First) (Middle)
    2525 EAST NORTH CAROLINA HIGHWAY 54

    (Street)
    DURHAM NC 27713

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Humacyte, Inc. [ HUMA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    President, CEO and Director
    3. Date of Earliest Transaction (Month/Day/Year)
    10/13/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options (right to buy) $10.03 10/13/2021 A 8,500 (1) 10/13/2031 Common Stock 8,500 $0 8,500 I By spouse
    Explanation of Responses:
    1. The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025.
    /s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact 10/15/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AHAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHAC

    DatePrice TargetRatingAnalyst
    7/20/2021$18.00Buy
    Benchmark
    7/20/2021$18.00Buy
    The Benchmark Company
    More analyst ratings

    $AHAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Scheessele William John

    4 - Humacyte, Inc. (0001818382) (Issuer)

    10/15/21 3:51:53 PM ET
    $AHAC
    Business Services
    Finance

    SEC Form 4 filed by Binder Gordon M

    4 - Humacyte, Inc. (0001818382) (Issuer)

    10/15/21 3:43:59 PM ET
    $AHAC
    Business Services
    Finance

    SEC Form 4 filed by Brown Emery N.

    4 - Humacyte, Inc. (0001818382) (Issuer)

    10/15/21 3:42:44 PM ET
    $AHAC
    Business Services
    Finance

    $AHAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Benchmark initiated coverage on Alpha Healthcare with a new price target

    Benchmark initiated coverage of Alpha Healthcare with a rating of Buy and set a new price target of $18.00

    7/20/21 7:58:11 AM ET
    $AHAC
    Business Services
    Finance

    The Benchmark Company initiated coverage on Alpha Healthcare Acquisition Corp. with a new price target

    The Benchmark Company initiated coverage of Alpha Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $18.00

    7/20/21 7:16:19 AM ET
    $AHAC
    Business Services
    Finance

    Lake Street initiated coverage on Alpha Healthcare Acquisition Corp. with a new price target

    Lake Street initiated coverage of Alpha Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $20.00

    4/9/21 8:42:45 AM ET
    $AHAC
    Business Services
    Finance

    $AHAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

    Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under "HUMA" and "HUMAW" on August 27, 2021Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications in vascular trauma, AV access and peripheral arterial diseaseCombined company will be led by Laura Niklason, M.D., Ph.D., Founder, President & CEO, and current executive teamKathleen Sebelius appointed Chair of the Board of DirectorsHumacyte to commemorate milestone by ringing Nasdaq closing bell on Monday, August 30, 2021 DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform

    8/26/21 4:05:00 PM ET
    $AHAC
    Business Services
    Finance

    Alpha Healthcare Acquisition Corp. Announces Shareholder Approval of Business Combination with Humacyte

    NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (NASDAQ:AHAC) ("AHAC"), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, and all other proposals presented at AHAC's special shareholder's meeting held on August 24, 2021. AHAC shareholders approved the business combination proposal with 99.5% votes in favor of the approximately 61.6% of AHAC votes cast at the meeting. AHAC plans to file the results of the

    8/24/21 12:58:48 PM ET
    $AHAC
    $DMTK
    Business Services
    Finance
    Medical Specialities
    Health Care

    Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels

    In addition to the Company's eight ongoing clinical trials, HAVs have been used in 13 expanded access cases for emergent life- and limb-saving vascular surgeries at seven hospitals across the U.S.Video testimonial features patient who experienced a traumatic leg injury and received the HAV to restore blood flow to her crushed limb DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced today the successful completion of its 13th Expanded Access Program (EAP) implant of its bioengineered blood vessel, the Human Acellular Vessel (HAV), in the U

    8/19/21 7:30:00 AM ET
    $AHAC
    $DMTK
    Business Services
    Finance
    Medical Specialities
    Health Care

    $AHAC
    SEC Filings

    View All

    SEC Form S-1 filed by Alpha Healthcare Acquisition Corp.

    S-1 - Humacyte, Inc. (0001818382) (Filer)

    9/17/21 4:59:30 PM ET
    $AHAC
    Business Services
    Finance

    Alpha Healthcare Acquisition Corp. filed SEC Form 8-K: Leadership Update

    8-K - Humacyte, Inc. (0001818382) (Filer)

    9/2/21 12:20:03 PM ET
    $AHAC
    Business Services
    Finance

    Alpha Healthcare Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Financial Statements and Exhibits, Leadership Update, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure

    8-K - Humacyte, Inc. (0001818382) (Filer)

    8/27/21 9:01:49 PM ET
    $AHAC
    Business Services
    Finance

    $AHAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp.

    SC 13G - Humacyte, Inc. (0001818382) (Subject)

    9/8/21 4:22:18 PM ET
    $AHAC
    Business Services
    Finance

    SEC Form SC 13D filed by Alpha Healthcare Acquisition Corp.

    SC 13D - Humacyte, Inc. (0001818382) (Subject)

    9/2/21 6:04:40 AM ET
    $AHAC
    Business Services
    Finance

    SEC Form SC 13D filed by Alpha Healthcare Acquisition Corp.

    SC 13D - Humacyte, Inc. (0001818382) (Subject)

    8/27/21 9:14:01 PM ET
    $AHAC
    Business Services
    Finance

    $AHAC
    Leadership Updates

    Live Leadership Updates

    View All

    Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

    Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under "HUMA" and "HUMAW" on August 27, 2021Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications in vascular trauma, AV access and peripheral arterial diseaseCombined company will be led by Laura Niklason, M.D., Ph.D., Founder, President & CEO, and current executive teamKathleen Sebelius appointed Chair of the Board of DirectorsHumacyte to commemorate milestone by ringing Nasdaq closing bell on Monday, August 30, 2021 DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform

    8/26/21 4:05:00 PM ET
    $AHAC
    Business Services
    Finance